FindTrial
Sign In

Transition from ambrisentan to bosentan in pulmonary arterial hypertension: A single center prospective study

Transition from ambrisentan to bosentan in pulmonary arterial hypertension: A single center prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-17013521
Enrollment
Unknown
Registered
2017-11-24
Start date
2015-02-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension

Interventions

ambrisentan group:oral ambrisentan
bosentan group:oral bosentan

Sponsors

Shanghai Pulmonary Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. All patients included are ethnic Chinese; 2. All patients with PAH disease in stable phase.

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

MeasureTime frame
6-minute walk distance;—

Countries

China

Contacts

Public ContactJin-Ming Liu
jinmingliu2013@126.com+86 13818181063

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026